Trial Profile
A randomized, crossover study to evaluate the impact of gastric acid reducing agents on pharmacokinetics of Sofosbuvir/Velpatasvir/Voxilaprevir fixed dose combination tablet.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2018
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary) ; Famotidine; Omeprazole
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 29 Mar 2018 New trial record
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics